FDA.reportPublic FDA data

Spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+

RxCUI
2691181
RxNorm name
Spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+
Display name
Spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+
Full name
Spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:29

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125752SpikevaxCOVID-19 Vaccine, mRNA351(a)Disc2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
f96b315c-fa57-4876-a7e5-a9b584d8e6e6Spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+SY10These highlights do not include all the information needed to use SPIKEVAX safely and effectively. See full prescribing information for SPIKEVAX . SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202220250827
f96b315c-fa57-4876-a7e5-a9b584d8e6e60.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (KP.2) 0.1 MG/ML Prefilled Syringe [Spikevax 2024-2025]SBD10These highlights do not include all the information needed to use SPIKEVAX safely and effectively. See full prescribing information for SPIKEVAX . SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202220250827
f96b315c-fa57-4876-a7e5-a9b584d8e6e6spikevax 2024-2025 vaccine, 0.5 ML Prefilled Syringe, 12y+PSN10These highlights do not include all the information needed to use SPIKEVAX safely and effectively. See full prescribing information for SPIKEVAX . SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202220250827